HeartBeam Management to Present at Key Investor and Medical Conferences in March 2026

HeartBeam, a medical technology company focused on transforming cardiac care, announced that its management team will participate in several investor and industry conferences in March 2026. CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation, while also meeting with institutional and retail investors. The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel discussion on technologies advancing healthy aging.

In addition, Eno, Founder and President Dr. Branislav Vajdic, and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology’s annual scientific conference on March 28-30. At this event, the company plans to showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners. This engagement is significant as it provides a direct platform to present the technology to key medical professionals and collaborators in the cardiology field.

The company’s technology represents an important development in cardiac care. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians could potentially identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, which may help redefine cardiac health management.

HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement. The conference participation underscores the company’s ongoing efforts to advance its commercial and clinical outreach following these regulatory milestones. For more information, the latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer.

The management’s scheduled appearances at these conferences highlight strategic steps to engage with the investment community and medical industry. Participation in events like the Oppenheimer and ROTH conferences allows for dialogue with investors, while the ACC.26 conference serves as a critical venue for demonstrating medical technology to cardiologists and potential partners. These activities are part of broader initiatives to promote the adoption of HeartBeam’s innovative cardiac monitoring solutions in the healthcare market.